Close

Pfizer (PFE) Gets FDA Approval for BOSULIF as Ph+ CML Treatment

September 4, 2012 4:17 PM EDT Send to a Friend
Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login